Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
Miguel Martín, Frankie Ann Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017
Cited by 585 works. doi:10.1016/s1470-2045(17)30717-9
Authors
- Miguel Martín
- Frankie Ann Holmes
- Bent Ejlertsen
- Suzette Delaloge
- Beverly Moy
- Hiroji Iwata
- Gϋnter von Minckwitz
- Stephen Chia
- Janine Mansi
- Carlos H. Barrios
- Michael Gnant
- Zorica I. Tomasevic
- Neelima Denduluri
- Robert Šeparović
- Erhan Gökmen
- Anna Bashford
- Manuel Ruíz Borrego
- Sung‐Bae Kim
- Erik Hugger Jakobsen
- Audrone Ciceniene
References
- Checking the Cox model with cumulative sums of martingale-based residuals
- Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP System
- Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
- Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
- Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31
- Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase
- Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831
- American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline